Cambridge Investment Research Advisors, Inc. Gain Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 59,500 shares of GANX stock, worth $98,175. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,500
Previous 54,500
9.17%
Holding current value
$98,175
Previous $118,000
3.39%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GANX
# of Institutions
38Shares Held
3.53MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$970,8760.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$934,1140.05% of portfolio
-
Jones Financial Companies Lllp428KShares$705,7050.0% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$465,6480.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$420,7330.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $19.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...